VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Cancer DNA Vaccine MIDGE/hNIS encoding hNIS protein
Vaccine Information
  • Vaccine Name: Cancer DNA Vaccine MIDGE/hNIS encoding hNIS protein
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0011364
  • Type: DNA vaccine
  • Status: Research
  • SLC5A5 gene engineering:
    • Type: DNA vaccine construction
    • Description: Human sodium iodide symporter (hNIS) is a transmembrane protein that actively transports iodide ions into thyroid cells. hNIS is over-expressed in some cases of the thyroid cancers compared with the surrounding normal tissues and has been considered to be an attractive target for immunotherapy. Minimalistic immunogenically defined gene expression (MIDGE) was used as a vector system (Choi et al., 2007).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid: pcDNA3.1 DNA vaccine plasmid
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Mouse Response

  • Host Strain: Balb/C
  • Vaccination Protocol: mice (4 per group) were vaccinated i.m. with 100 μg per mouse of pcDNA3.1 or pcDNA3.1/hNIS in a 100 μl volume. The groups primed with MIDGE/hNIS or MIDGE/hNIS-NLS received 54.8 μg/100 μl per mouse, which is an equimolar concentration of the plasmids. One week later, the mice were boosted with the same amount of DNA (Choi et al., 2007).
  • Challenge Protocol: One week after the final vaccination, the mice were challenged subcutaneously (s.c.) with CT26/NIS tumor cells at 5 × 104 cells/mouse in the hind-right legs (Choi et al., 2007).
  • Efficacy: Immunization with the hNIS encoding vectors induced antigen-mediated antitumor activity against NIS-expressing CT26 tumors in vivo, with the highest tumor free rate (100%) and lowest tumor growth being observed up to 40 days after the CT26/NIS tumor challenge with MIDGE/hNIS than those resulting from other immunization groups (Choi et al., 2007).
References
Choi et al., 2007: Choi Y, Jeon YH, Kang JH, Chung JK, Schmidt M, Kim AC. MIDGE/hNIS vaccination generates antigen-associated CD8+IFN-gamma+ T cells and enhances protective antitumor immunity. International journal of cancer. Journal international du cancer. 2007; 120(9); 1942-1950. [PubMed: 17266027].